2019 American Transplant Congress
Utilization of LCP-Tacrolimus (ENVARSUS XR) in Simultaneous Pancreas and Kidney (SPK) Transplant Recipients
Montefiore Medical Center, Bronx, NY
*Purpose: The use of extended release tacrolimus (LCPT) allows for slow release of drug and once-daily dosing in transplant recipients. The improved bioavailability and decreased…2019 American Transplant Congress
Breaking Concepts: 10-year Follow-Up of the Everolimus versus Azathioprine Heart Transplant Multi-National Study
*Purpose: This study is the 10-year follow-up of a randomized double-blind prospective trial that compared everolimus (1.5 mg or 3 mg) to azathioprine. In this…2019 American Transplant Congress
Belatacept Treated Patients Experience Improved Health-Related Quality of Life and Lower Symptom Distress Compared to Cyclosporine Treated Patients: An Analysis of the Benefit and Benefit-EXT Cohorts
1Terasaki Research Institute, Los Angeles, CA, 2Bristol Myers Squibb, Princeton, NJ
*Purpose: New immunosuppressive agents in transplant should not only be efficacious but also help patients feel better (i.e. lower patient reported symptoms and improve health…2019 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
1Surgery, Duke University, Durham, NC, 2University of Massachusetts, Worcester, MA
*Purpose: Porcine islet xenotransplantation has progressed significantly in non-human primate (NHP) studies. However, all successful NHP studies have relied upon immunosuppressive regimens that utilize drugs…2019 American Transplant Congress
Effect of ATG on Monocytic Myeloid-Derived Suppressor Cells and Its Associated Mechanisms in Kidney Transplantation Recipients
Beijing Chao-yang Hospital, Beijing, China
*Purpose: Myeloid-derived suppressor cells (MDSCs) consist of heterogeneous myeloid progenitors and precursors that was first defined in cancer patients and are characterized by a immunoregulatory…2019 American Transplant Congress
Efficacy of Belatacept Conversion Protocols
Kaiser Los Angeles Medical Center, Los Angeles, CA
*Purpose: Belatacept (bela) is approved for de novo use in kidney transplantation. Conversion from CNI to bela is utilized for various reasons. Conversion is off-label…2019 American Transplant Congress
Abatacept as Rescue Immunosuppression after Calcineurin Inhibitor Treatment Failure in Renal Transplantation
Emory University School of Medicine, Atlanta, GA
*Purpose: A majority of kidney transplant recipients receive calcineurin inhibitor (CNI)-based immunosuppression. However, some do not tolerate CNIs and require other immunosuppressive strategies. Until recently,…2019 American Transplant Congress
Urinary Biomarkers of Kidney Injury in Liver Transplant Recipients with Calcineurin Inhibitors Based Immunosuppression
1UTHSC, Memphis, TN, 2Transplant Institute, Memphis, TN
*Purpose: Renal dysfunction post solid organ transplantation is common and associated with several risk factors. Messenger RNA encoding for genes expressed along the nephron and…2019 American Transplant Congress
A Cluster of Late Onset of Pneumocystis jirovecii Pneumonia (PJP) in Renal Transplant Patients: First Cluster Report from Saudi Arabia
King Fahad specialist hospital - Dammam, Dammam, Saudi Arabia
*Purpose: Pneumocystis jiroveci pneumonia (PJP) is a serious opportunistic infection that can be associated with severe pulmonary involvement in transplant population. Post-transplant protocol at our…2019 American Transplant Congress
Risk Factors for Sensitization in the Failing Allograft: A Multi-Center Experience
*Purpose: Sensitization is frequent after an allograft fails and makes re-transplant difficult for many patients.*Methods: We performed a cross-sectional chart review of patients who were…
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 138
- Next Page »